Barbara Ramona-Rita, Pawaroo Davina, Beadsmoore Clare, Hujairi Nabil, Newman David
Norwich Radiology Academy, The Cotman Centre, Norwich.
Royal Marsden Hospital, London, UK.
Nucl Med Commun. 2019 Mar;40(3):264-269. doi: 10.1097/MNM.0000000000000961.
The increased use of PET/CT in cancer staging has resulted in more incidental findings in unexpected locations, making this a challenge for the radiologist interpreting the study. Our aim was to determine the frequency of parotid incidentalomas and to assess the ability of PET/CT to characterize them.
At the Norfolk and Norwich University Trust, in between October 2010 to October 2015, 4044 patients had a PET/CT examination. The issued clinical reports that contained the word 'parotid' were traced and all patients selected for this study had no known or suspected parotid disease before the PET/CT scan.
The prevalence of parotid incidentalomas was 1.73%; higher than expected as was the mean age of our study group. Ten per cent of patients had no focal lesion identified on subsequent ultrasound. Thirty-two per cent of patients had a biopsy which showed that the majority of these findings were benign and 13% had metastatic deposits, with the primary carcinoma in these cases being neuroendocrine colon carcinoma, non-Hodgkin's lymphoma and melanoma.
The most common benign salivary tumour in our study was Warthin's tumour and the majority of these patients had a primary lung carcinoma. Given that the main predisposing factor for both pathologies is smoking, potentially this suggests an association between the incidence of primary lung carcinoma and Warthin's tumour. Ten (14%) patients in our study had a standardized uptake value of below 3.2 (using the VUE Point HD algorithm). These patients had either no identifiable lesion on ultrasound or no malignant features on histology; therefore, we propose that a cut-off of 3.2 on PET/CT could be used to differentiate between physiological or benign uptake from malignant fluorine-18-fluorodeoxyglucose uptake in the parotid gland.
PET/CT在癌症分期中的使用增加,导致在意外部位出现更多偶然发现,这给解读该检查结果的放射科医生带来了挑战。我们的目标是确定腮腺偶发瘤的发生率,并评估PET/CT对其进行特征描述的能力。
在诺福克和诺维奇大学信托医院,2010年10月至2015年10月期间,4044例患者接受了PET/CT检查。追踪发出的包含“腮腺”一词的临床报告,所有入选本研究的患者在PET/CT扫描前均无已知或疑似腮腺疾病。
腮腺偶发瘤的患病率为1.73%;高于预期,我们研究组的平均年龄也是如此。10%的患者在后续超声检查中未发现局灶性病变。32%的患者进行了活检,结果显示这些发现大多为良性,13%有转移灶,这些病例中的原发性癌为神经内分泌结肠癌、非霍奇金淋巴瘤和黑色素瘤。
我们研究中最常见的良性唾液腺肿瘤是沃辛瘤,这些患者大多数患有原发性肺癌。鉴于这两种疾病的主要诱发因素都是吸烟,这可能表明原发性肺癌的发病率与沃辛瘤之间存在关联。我们研究中的10例(14%)患者的标准化摄取值低于3.2(使用VUE Point HD算法)。这些患者在超声检查中要么没有可识别的病变,要么在组织学上没有恶性特征;因此,我们建议PET/CT上3.2的临界值可用于区分腮腺中生理性或良性摄取与恶性氟-18-氟脱氧葡萄糖摄取。